Press Releases See All 05/31/2023 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 05/24/2023 Sarepta Therapeutics Announces Update on Regulatory Review of SRP-9001 05/12/2023 Sarepta Therapeutics Announces Positive Vote from U.S. FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy Stories & Perspectives Filter by: Filter by: All Advocates & Innovators Culture & Community Inside the Science Patient Voices Filter by: AllAdvocates & InnovatorsCulture & CommunityInside the SciencePatient Voices Advocates & Innovators Seeing hope at genetic medicine's frontier: Meet Stefanie Mason, M.D. Inside the Science Why are steroids used in gene therapy for neuromuscular disease? Advocates & Innovators A passion for patients, an influential mentor and a change in plans: Meet Danielle Griffin Patient Voices Creating pathways to LGMD genetic diagnosis: Spotlight on LGMD Grant Award recipient Advocates & Innovators Ensuring the safety of clinical trial participants: Meet Eddie Darton, M.D. Advocates & Innovators Dragging tomorrow into today: Meet Rachael Potter, Ph.D. Inside the Science Understanding external controls and their importance to clinical trials for rare diseases Inside the Science Meaningful measure: Understanding the NSAA, an important Duchenne functional-assessment tool Culture & Community What’d you do this summer? Our summer interns share lessons learned Culture & Community Pride proud: What belonging feels like and why representation matters Advocates & Innovators A conversation with CFO Ian Estepan, recipient of the 2022 CFO of the Year award from the Boston Business Journal Inside the Science Seroprevalence: What patients should know about pre-existing antibodies to gene therapy Inside the Science Patient registries: A catalyst for developing new therapies for rare diseases Inside the Science Measurements used in clinical trials for Duchenne muscular dystrophy – an overview Advocates & Innovators How a collaboration in the lab led to a seat at the table in Sarepta’s Gene Editing Innovation Center Culture & Community Giving thanks for our employees’ incredible dedication: Six employees explain why Sarepta is a Top Place to Work Inside the Science Welcome to GT‐FAQ! Advocates & Innovators Expanding access to newborn screening for those with rare diseases Patient Voices Patiently waiting Advocates & Innovators From art to science: How one Sarepta scientist brings arts into the lab Patient Voices Advocacy community unites to support families Culture & Community How Sarepta infused its corporate brand with urgency and optimism on behalf of patients Inside the Science What’s in a name? A lot, for the limb-girdle muscular dystrophy community. Media Library Sarepta Corporate Logos, Images & Fact Sheets View All Press Contact Tracy Sorrentino Executive Director, Public Relations Sarepta Therapeutics, Inc.[email protected]617-274-4052
05/12/2023 Sarepta Therapeutics Announces Positive Vote from U.S. FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy
Advocates & Innovators A passion for patients, an influential mentor and a change in plans: Meet Danielle Griffin
Inside the Science Understanding external controls and their importance to clinical trials for rare diseases
Inside the Science Meaningful measure: Understanding the NSAA, an important Duchenne functional-assessment tool
Advocates & Innovators A conversation with CFO Ian Estepan, recipient of the 2022 CFO of the Year award from the Boston Business Journal
Inside the Science Seroprevalence: What patients should know about pre-existing antibodies to gene therapy
Inside the Science Measurements used in clinical trials for Duchenne muscular dystrophy – an overview
Advocates & Innovators How a collaboration in the lab led to a seat at the table in Sarepta’s Gene Editing Innovation Center
Culture & Community Giving thanks for our employees’ incredible dedication: Six employees explain why Sarepta is a Top Place to Work
Culture & Community How Sarepta infused its corporate brand with urgency and optimism on behalf of patients